[1] Loguercio C, Festi D.Silybin and the liver: from basic research to clinical practice[J].World J Gastroenterol,2011,17(18):2288-2301. [2] Gazák R, Walterová D, Kren V.Silybin and silymarin——new and emerging applications in medicine[J].Curr Med Chem,2007,14(3):315-338. [3] Soto CP,Perez BL,Favari LP,et al. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin[J].Comp Biochem Physiol C,1998,119(2):125-129. [4] Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes[J]. Diabetologia,2008,51(2):216-226. [5] Soto C,Mena R,Luna J,et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats [J].Life Sci,2004,75(18):2167-2180. [6] Huseini HF,Larijani B, Heshmat R,et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial[J].Phytother Res,2006,20(12):1036-1039. [7] Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes[J].J Med Food,2007,10(3):543-547. [8] Trouillas P,Marsal P,Svobodová A,et al. Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study[J].J Phys Chem A,2008,112(5): 1054-1063. [9] Comoglio A,Tomasi A,Malandrino S,et al. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals[J].Biochem Pharmacol,1995,50(8):1313-1316. [10] Fu H,Katsumura Y,Lin M,et al. Fast repair activities towards dGMP hydroxyl radical adducts by silybin and its analogues[J].J Radiat Res,2008,49(6): 609-614. [11] Täger M,Dietzmann J, Thiel U,et al. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin[J].Free Radic Res,2001,34(2):137-151. [12] Soto C,Recoba R,Barrón H,et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas[J].Comp Biochem Physiol C,2003,136(3):205-212. [13] Tong S,Chu C,Wei Y,et al. Preparation and effects of 2,3-dehydrosilymarin, a promising and potent antioxidant and free radical scavenger[J].J Pharm Pharmacol,2011,63(2):238-244. [14] Abdelli S,Abderrahmani A,Hering BJ,et al. The c-Jun N-terminal kinase JNK participates in cytokine- and isolation stress-induced rat pancreatic islet apoptosis[J].Diabetologia,2007,50(8):1660-1669. [15] Kim WH,Lee JW,Gao B,et al. Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway[J].Cell Signal,2005,17(12):1516-1532. [16] Matsuda T,Ferreri K,Todorov I,et al. Silymarin protects pancreatic β-cells against cytokine-mediated toxicity: Implication of c-Jun NH2-terminal kinase and Janus kinase/signal transducer and activator of transcription pathways[J].Endocrinology,2005,146(1):175-185. [17] Kang JS,Jeon YJ,Park SK,et al. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1β and prostaglandin E2 synthesis by silymarin[J].Biochem Pharmacol,2004,67(1):175-181. [18] Cho JY,Kim PS,Park J,et al. Inhibitor of tumor necrosis factor-α production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa[J].J Ethnopharmacol,2000,70(2):127-133. [19] Azevedo-Martins AK,Lortz S,Lenzen S,et al. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells[J].Diabetes,2003,52(1):93-101. [20] van Raalte DH, Diamant M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy[J].Diabetes Res Clin Pract,2011,93 (Suppl 1):S37-46. [21] Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes[J].Biochem Soc Trans,2008,36(3):348-352. [22] Poitout V,Amyot J,Semache M,et al. Glucolipotoxicity of the pancreatic beta cell[J].Biochimica Biophysica Acta,2010,1801(3):289-298. [23] Unger RH, Clark GO, Scherer PE,et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome[J].Biochim Biophys Acta,2010,1801(3):209-214. [24] Unger RH,Zhou YT,Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin[J].Proc Natl Acad Sci USA,1999,96(5):2327-2332. [25] Yamashita T,Eto K,Okazaki Y,et al. Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c[J].Endocrinology,2004,145(8):3566-3577. [26] Attie D. Insig: a significant integrator of nutrient and hormonal signals[J].J Clin Invest,2004,113(8):1112-1114. [27] McPherson R, Gauthier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis[J].Biochem Cell Biol,2004,82(1):201-211. [28] Chen K,Jin P,He HH,et al. Overexpression of Insig-1 protects β cell against glucolipotoxicity via SREBP-1c[J].J Biomed Sci,2011,18:57. [29] Ka SO,Kim KA,Kwon KB,et al. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway[J].Int J Mol Med,2009,23(5):633-637. [30] Yao J,Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats[J].Braz J Med Biol Res,2011,44(7):652-659. [31] Velussi M,Cernigoi AM,De Monte A,et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients[J].J Hepatol,1997 ,26(4):871-879. [32] 叶建红,黎锋,李芳萍,等. 水飞蓟宾对代谢综合征患者葡萄糖代谢率与脂肪因子的影响[J].中国老年学杂志,2011,31(3):374-376. [33] Wang Q, Liu M, Liu WW, et al. In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic β-cell[J].J Asian Nat Prod Res,2012,14(5):413-423. [34] Cheng B, Gong H, Li X, et al. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide[J].Biochem Biophys Res Commun,2012,419(3):495-499. |